Cargando…

Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity

Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial growth factor-, and platelet-derived growth factor receptors. These three receptors promote new blood vessel formation and maintenance, which is essential for tumor growth and spread. Several trials have sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Shu, Xue, Shuyu, Wang, Tiantian, Gao, Ruihang, Zeng, Hanqiao, Wang, Qianmeng, Jia, Xiaojing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449572/
https://www.ncbi.nlm.nih.gov/pubmed/37637045
http://dx.doi.org/10.3389/fonc.2023.1086214
_version_ 1785094982668910592
author Yan, Shu
Xue, Shuyu
Wang, Tiantian
Gao, Ruihang
Zeng, Hanqiao
Wang, Qianmeng
Jia, Xiaojing
author_facet Yan, Shu
Xue, Shuyu
Wang, Tiantian
Gao, Ruihang
Zeng, Hanqiao
Wang, Qianmeng
Jia, Xiaojing
author_sort Yan, Shu
collection PubMed
description Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial growth factor-, and platelet-derived growth factor receptors. These three receptors promote new blood vessel formation and maintenance, which is essential for tumor growth and spread. Several trials have shown that nintedanib plays a substantial role in treating patients with non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis. Recently, several clinical trials of nintedanib to treat NSCLC have been reported. In this review, we focus on our current understanding of nintedanib treatment for advanced NSCLC patients and summarize the literature on using nintedanib in radiation-induced lung toxicity and the efficacy and tolerability of nintedanib.
format Online
Article
Text
id pubmed-10449572
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104495722023-08-25 Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity Yan, Shu Xue, Shuyu Wang, Tiantian Gao, Ruihang Zeng, Hanqiao Wang, Qianmeng Jia, Xiaojing Front Oncol Oncology Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial growth factor-, and platelet-derived growth factor receptors. These three receptors promote new blood vessel formation and maintenance, which is essential for tumor growth and spread. Several trials have shown that nintedanib plays a substantial role in treating patients with non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis. Recently, several clinical trials of nintedanib to treat NSCLC have been reported. In this review, we focus on our current understanding of nintedanib treatment for advanced NSCLC patients and summarize the literature on using nintedanib in radiation-induced lung toxicity and the efficacy and tolerability of nintedanib. Frontiers Media S.A. 2023-08-10 /pmc/articles/PMC10449572/ /pubmed/37637045 http://dx.doi.org/10.3389/fonc.2023.1086214 Text en Copyright © 2023 Yan, Xue, Wang, Gao, Zeng, Wang and Jia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yan, Shu
Xue, Shuyu
Wang, Tiantian
Gao, Ruihang
Zeng, Hanqiao
Wang, Qianmeng
Jia, Xiaojing
Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
title Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
title_full Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
title_fullStr Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
title_full_unstemmed Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
title_short Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
title_sort efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449572/
https://www.ncbi.nlm.nih.gov/pubmed/37637045
http://dx.doi.org/10.3389/fonc.2023.1086214
work_keys_str_mv AT yanshu efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity
AT xueshuyu efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity
AT wangtiantian efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity
AT gaoruihang efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity
AT zenghanqiao efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity
AT wangqianmeng efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity
AT jiaxiaojing efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity